Literature DB >> 408379

Some effects of calcium on the activation of human factor VIII/Von Willebrand factor protein by thrombin.

M E Switzer, P A McKee.   

Abstract

When Factor VIII/von Willebrand factor (FVIII/vWF) protein is rechromatographed on 4% agarose in 0.25 M CaCl(2), the protein and vWF activity appear in the void volume, but most of the FVIII procoagulant activity elutes later. Recent evidence suggests that the delayed FVIII procoagulant activity is a proteolytically modified form of FVIII/vWF protein that filters anomalously from agarose in 0.25 M CaCl(2). To test whether or not thrombin is the protease involved, the effect of 0.25 M CaCl(2) on FVIII/vWF and its reaction with thrombin was examined. About 30% of the FVIII procoagulant activity was lost immediately when solutions of FVIII/vWF protein were made 0.25 M in CaCl(2). When FVIII in 0.15 M NaCl was activated with 0.04 U thrombin/ml and then made 0.25 M in CaCl(2), the procoagulant activity of a broad range of FVIII/vWF protein concentrations remained activated for at least 6 h. But, in 0.25 M CaCl(2), the increase in FVIII procoagulant activity in response to thrombin was much more gradual and once activated, the procoagulant activity was stabilized by 0.25 M CaCl(2). When thrombin-activated FVIII/vWF protein was filtered on 4% agarose in 0.15 M NaCl, there was considerable inactivation of FVIII procoagulant activity; however, the procoagulant activity that did remain eluted in the void volume. In contrast, when thrombin-activated FVIII/vWF protein was filtered in 0.25 M CaCl(2), the FVIII procoagulant activity eluted well after the void volume and remained activated for 6 h. The procoagulant peak isolated by filtering nonthrombin-activated FVIII/vWF protein on agarose in 0.25 M CaCl(2) was compared to that isolated from thrombin-activated FVIII/vWF protein. Both procoagulant activity peak proteins had about the same specific vWF activity as the corresponding void volume protein. Before reduction, the sodium dodecyl sulfate gel patterns for the two procoagulant activity peak proteins were the same. After reduction, the gel pattern for the nonthrombin-activated procoagulant activity peak protein contained bands of 195,000, 148,000-120,000, 79,000, 61,000, 51,000, and 18,000 daltons whereas the pattern for the reduced thrombin-activated procoagulant activity peak protein always lacked the higher molecular weight bands, but consistently showed the four lower molecular weight bands to be well resolved. Taken together, these results imply that thrombin generates the FVIII procoagulant activity that is stabilized by 0.25 M CaCl(2) and elutes aberrantly from 4% agarose in that solvent.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 408379      PMCID: PMC372430          DOI: 10.1172/JCI108836

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  A study of the cation- and pH-dependent stability of factors V and VIII in plasma.

Authors:  H J Weiss
Journal:  Thromb Diath Haemorrh       Date:  1965-09-01

2.  Spontaneous aggregation of low molecular weight factor viii and its prevention by 2mm cacl2.

Authors:  I I Sussman; H J Weiss
Journal:  Thromb Res       Date:  1976-09       Impact factor: 3.944

3.  Nature of von Willebrand factor: a new assay and a specific inhibitor.

Authors:  K E Sarji; R D Stratton; R H Wagner; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

4.  Plasma aggregating factor (bovine) for human platelets: a marker for study of antihemophilic and von Willebrand Factors.

Authors:  T R Griggs; H A Cooper; W P Webster; R H Wagner; K M Brinkhous
Journal:  Proc Natl Acad Sci U S A       Date:  1973-10       Impact factor: 11.205

5.  Von Willebrand factor: dissociation from antihemophilic factor procoagulant activity.

Authors:  H J Weiss; I W Hoyer
Journal:  Science       Date:  1973-12-14       Impact factor: 47.728

6.  Studies on the nature of antihemophilic factor (factor VIII). Further evidence relating the AHF-like antigens in normal and hemophilic plasmas.

Authors:  B Bennett; W B Forman; O D Ratnoff
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

7.  The subunit structure of normal and hemophilic factor VIII.

Authors:  G A Shapiro; J C Andersen; S V Pizzo; P A McKee
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

8.  Defective ristocetin-induced platelet aggregation in von Willebrand's disease and its correction by factor VIII.

Authors:  H J Weiss; J Rogers; H Brand
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  The defect in hemophilic and von Willebrand's disease plasmas studied by a recombination technique.

Authors:  H A Cooper; R H Wagner
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

10.  Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.

Authors:  H J Weiss; L W Hoyer; F R Rickles; A Varma; J Rogers
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

View more
  1 in total

1.  Interaction of factor VIII-von Willebrand Factor with phospholipid vesicles.

Authors:  L O Andersson; J E Brown
Journal:  Biochem J       Date:  1981-10-15       Impact factor: 3.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.